載入...
miR-579-3p controls melanoma progression and resistance to target therapy
Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the devel...
Na minha lista:
發表在: | Proc Natl Acad Sci U S A |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
National Academy of Sciences
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5003278/ https://ncbi.nlm.nih.gov/pubmed/27503895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607753113 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|